After a 2 week screening period all eligible participants were randomly assigned to treatment groups receiving either a subcutaneous injection of 2.4 mg of semaglutide, 2.4 mg of cagrilintide, a combination of cagrilintide and semaglutide, a semaglutide placebo, or a cagrilintide placebo [2]
With a 3.33mg/mL concentration, a 2.4mg dose requires 72 units, which needs a 1.0mL (100 unit) syringe
For opened vials, refrigeration is recommended to maintain preservative integrity
Research stage: Early pre-clinical and limited clinical research, some veterinary applications
treat promptly per standard of care, and monitor until signs and symptoms resolve
Researchers working with human subjects can track outcomes using several practical approaches